Use of the Absorb bioresorbable vascular scaffold (BVS, Abbott Vascular) is associated with an increased risk of definite or probable scaffold thrombosis at 1 year and beyond, as well as increased ...

Even though Bravura Solutions Limited (ASX:BVS) posted strong earnings, investors appeared to be underwhelmed. We did some digging and actually think they are being unnecessarily pessimistic. We've ...

In patients with very long coronary lesions, use of Absorb BVS (Abbott Vascular) is associated with a high rate of TLF at 1 year, driven by MI and clinically driven TLR, according to a subanalysis ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Please provide your email address to receive an email when new articles are posted on . Bioresorbable vascular scaffolds appear to be associated with a higher risk for very late device thrombosis ...

View Bioventus, Inc. Class A BVS stock quote prices, financial information, real-time forecasts, and company news from CNN.

Bioventus (BVS) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.07 per share a year ago. These figures are ...